Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
